Prijeđi na sadržaj

Lurasidon

Izvor: Wikipedija
Lurasidon
Klinički podaci
AHFS/Drugs Monografija
Identifikatori
CAS broj 367514-87-2
ATC kod N05AE05
PubChem[1][2] 213046
DrugBank DB08815
ChemSpider[3] 184739
ChEBI CHEBI:70735DaY
ChEMBL[4] CHEMBL1237021DaY
Hemijski podaci
Formula C28H36N4O2S
Mol. masa 492,676
SMILES eMolekuli&PubHem
Farmakokinetičkipodaci
Poluvreme eliminacije 18 h
Izlučivanje Renalno (~9%), fekalno (~80%)
Farmakoinformacioni podaci
Trudnoća ?
Pravni status
Način primene Oralno

Lurasidonjeorgansko jedinjenje,koje sadrži 28atomaugljenikai imamolekulsku masuod 492,676Da.[5][6][7][8]

Osobine

[uredi|uredi kod]
Osobina Vrednost
Broj akceptora vodonika 5
Broj donora vodonika 0
Broj rotacionih veza 5
Particioni koeficijent[9](ALogP) 4,9
Rastvorljivost[10](logS,log(mol/L)) -5,4
Polarna površina[11](PSA,Å2) 85,0

Reference

[uredi|uredi kod]
  1. Li Q, Cheng T, Wang Y, Bryant SH (2010).„PubChem as a public resource for drug discovery.”.Drug Discov Today15(23-24): 1052-7.DOI:10.1016/j.drudis.2010.10.003.PMID20970519.edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”.Annual Reports in Computational Chemistry4:217-241.DOI:10.1016/S1574-1400(08)00012-1.
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010).„Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”.J Cheminform2(1): 3.DOI:10.1186/1758-2946-2-3.PMID20331846.edit
  4. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”.Nucleic Acids Res40(Database issue): D1100-7.DOI:10.1093/nar/gkr777.PMID21948594.edit
  5. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Apr 2.PMID23545936
  6. Tarazi FI, Stahl SM: Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother. 2012 Sep;13(13):1911-22. doi: 10.1517/14656566.2012.712114. Epub 2012 Jul 31.PMID22849428
  7. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011).„DrugBank 3.0: a comprehensive resource for omics research on drugs”.Nucleic Acids Res.39(Database issue): D1035-41.DOI:10.1093/nar/gkq1126.PMC3013709.PMID21059682.edit
  8. David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008).„DrugBank: a knowledgebase for drugs, drug actions and drug targets”.Nucleic Acids Res36(Database issue): D901-6.DOI:10.1093/nar/gkm958.PMC2238889.PMID18048412.edit
  9. Ghose, A.K., Viswanadhan V.N., and Wendoloski, J.J. (1998).„Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”.J. Phys. Chem. A102:3762-3772.DOI:10.1021/jp980230o.
  10. Tetko IV, Tanchuk VY, Kasheva TN, Villa AE. (2001).„Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”.Chem Inf. Comput. Sci.41:1488-1493.DOI:10.1021/ci000392t.PMID11749573.edit
  11. Ertl P., Rohde B., Selzer P. (2000).„Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”.J. Med. Chem.43:3714-3717.DOI:10.1021/jm000942e.PMID11020286.edit

Literatura

[uredi|uredi kod]

Spoljašnje veze

[uredi|uredi kod]